Is it ever safe to stop anti-VEGF in patients with nAMD

Is it going to be ‘death do us part’, or can some patients stop anti-VEGF injections without a recurrence? Watch this talk to find out.

Papers discussed:
Scoles, D. et al. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial. JAMA Ophthalmol 138, 276 (2020).

Arendt, P. et al. EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Retina 39, 27–33 (2019).

Haddad, W.-M., Minous, F. L., Legeai, J. & Souied, E. H. LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Retina 37, 951–961 (2017).

Muftuoglu, I. K. et al. LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Retina 38, 516–522 (2018).

Nguyen, V. et al. Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Ophthalmology Retina 3, 623–628 (2019).

Hwang, R. Y., Santos, D. & Oliver, S. C. N. RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY: Retina 40, 679–685 (2020).

Adrean, S. D., Chaili, S., Grant, S. & Pirouz, A. Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat–Extend–Stop Protocol. Ophthalmology Retina 2, 225–230 (2018).

Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R. & Zhang, K. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON. Ophthalmology 120, 2292–2299 (2013).